Bioequivalence of Saxagliptin/Metformin Extended-Release (XR) Fixed-Dose Combination Tablets and Single-Component Saxagliptin and Metformin XR Tablets in Healthy Adult Subjects

被引：0
|
作者：
David W. Boulton
Charles H. Smith
L. Li
Jian Huang
Angela Tang
Frank P. LaCreta
机构：
[1] Bristol-Myers Squibb,
[2] PPD,undefined
来源：
Clinical Drug Investigation | 2011年 / 31卷
关键词：
Metformin; Saxagliptin; Tablet Core; Healthy Adult Subject; Initial Combination Therapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Background and Objectives: As compared with individual tablets, saxagliptin/metformin extended-release (XR) fixed-dose combination (FDC) tablets offer potential for increased patient compliance with the convenience of once-daily dosing. Two bioequivalence studies assessed the fed-state bioequivalence of saxagliptin/metformin XR 5 mg/500 mg FDC (study 1) and saxagliptin/metformin XR 5mg/1000 mg FDC (study 2) relative to the same dosage strengths of individual component tablets administered concurrently. The effect of food on saxagliptin and metformin pharmacokinetics from the saxagliptin/metformin XR 5 mg/500 mg FDC and their steady-state pharmacokinetics from the saxagliptin/metformin XR 5 mg/1000 mg were also investigated.
引用
收藏
页码：619 / 630
页数：11
相关论文
共 50 条
  • [21] Bioequivalence of a fixed-dose repaglinide/ metformin combination tablet and equivalent doses of repaglinide and metformin tablets
    Cho, Hea-Young
    Ngo, Lien
    Kim, Sang-Ki
    Choi, Yoonho
    Lee, Yong-Bok
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2018, 56 (06) : 292 - 300
  • [22] Bioequivalence and Food Effect of Dapagliflozin/Saxagliptin/Metformin Extended-release Fixed-combination Drug Products Compared With Coadministration of the Individual Components in Healthy Subjects
    Tang, Weifeng
    Engman, Helena
    Zhu, Yali
    Dayton, Brian
    Boulton, David W.
    CLINICAL THERAPEUTICS, 2019, 41 (08) : 1545 - 1563
  • [23] Bioequivalence of Sitagliptin/Metformin Fixed-Dose Combination Tablets and Concomitant Administration of Sitagliptin and Metformin in Healthy Adult Subjects A Randomized, Open-Label, Crossover Study
    Migoya, Elizabeth M.
    Miller, Jutta L.
    Gutierrez, Maria
    Zheng, Wei
    Johnson-Levonas, Amy O.
    Liu, Qi
    Matthews, Catherine Z.
    Wagner, John A.
    Gottesdiener, Keith M.
    CLINICAL DRUG INVESTIGATION, 2010, 30 (12) : 855 - 866
  • [24] Bioequivalence and food effect assessment for vildagliptin/metformin fixed-dose combination tablets relative to free combinations of vildagliptin and metformin in Japanese healthy subjects
    Mita, Sachiko
    Chitnis, Shripad D.
    Kulmatycki, Kenneth
    Salunke, Atish
    Het, Yan-Ling
    Zhou, Wei
    Suzuki, Hikoe
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2016, 54 (04) : 305 - 314
  • [25] BIOEQUIVALENCE OF FIXED DOSE COMBINATION (FDC) TABLETS OF LINAGLIPTIN/METFORMIN EXTENDED RELEASE COMPARED WITH THE FREE COMBINATIONS IN HEALTHY VOLUNTEERS
    Lippert, C.
    Sennewald, R.
    Bell, J.
    Wiebe, S.
    Huettner, S.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2016, 99 : S32 - S32
  • [26] BUDGET IMPACT ANALYSIS OF THE INTRODUCTION OF SAXAGLIPTIN/METFORMIN EXTENDED-RELEASE (XR) IN THE TREATMENT OF TYPE-2 DIABETES IN CHILE
    Elgart, J. F.
    Gonzalez, L.
    Aiello, E. C.
    Gagliardino, J. J.
    VALUE IN HEALTH, 2013, 16 (03) : A159 - A160
  • [27] BIOEQUIVALENCE OF FIXED DOSE COMBINATION (FDC) TABLETS OF EMPAGLIFLOZIN/METFORMIN EXTENDED RELEASE COMPARED WITH THE FREE COMBINATIONS IN HEALTHY VOLUNTEERS.
    Lippert, C.
    Sennewald, R.
    Elsasser, U.
    Huettner, S.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 101 (S1) : S74 - S74
  • [28] Bioequivalence (BE) of Saxagliptin (SAXA)/Dapagliflozin (DAPA) Fixed Dose Combination (FDC) Tablets Compared with Coadministration of the Individual Tablets
    Vakkalagadda, Blisse
    Vetter, Marion
    Rana, Jignasa
    Smith, Charles H.
    Haung, Jian
    Karkas, Jennifer
    Boulton, David W.
    Lacreta, Frank
    DIABETES, 2015, 64 : A325 - A325
  • [29] Short-term therapy with combination dipeptidyl peptidase-4 inhibitor saxagliptin/metformin extended release (XR) is superior to saxagliptin or metformin XR monotherapy in prediabetic women with polycystic ovary syndrome: a single-blind, randomized, pilot study
    Elkind-Hirsch, Karen E.
    Paterson, Martha S.
    Seidemann, Ericka L.
    Gutowski, Hanh C.
    FERTILITY AND STERILITY, 2017, 107 (01) : 253 - +
  • [30] Bioequivalence of Sitagliptin/Metformin Fixed-Dose Combination Tablets and Concomitant Administration of Sitagliptin and Metformin in Healthy Adult SubjectsA Randomized, Open-Label, Crossover Study
    Elizabeth M. Migoya
    Jutta L. Miller
    Maria Gutierrez
    Wei Zheng
    Amy O. Johnson-Levonas
    Qi Liu
    Catherine Z. Matthews
    John A. Wagner
    Keith M. Gottesdiener
    Clinical Drug Investigation, 2010, 30 : 855 - 866
12345